• BioNanomatrix Inc., of Philadelphia, closed a $23.3 million Series B round. Domain Associates led the round with participation from new investor Gund Investment Corp. and existing investors Battelle Ventures, Innovation Valley Partners and KT Venture group. BioNanomatrix is developing nanoscale, single-molecule imaging and analysis platforms designed to reduce the time and cost of analyzing genomes.

• Threshold Pharmaceuticals Inc., of Redwood City, Calif., completed its $30 million registered direct offering of 14.3 million shares and warrants for about 5.7 million shares. Net proceeds are expected to be about $27.8 million and will be used to support clinical trials of TH-302 and for additional product discovery R&D, working capital and other general corporate purposes. (See BioWorld Today, March 14, 2011.)